John Hood
Chief Executive Officer at Actavalon, Inc.
Profile
John Hood is the founder of Biosplice Therapeutics, Inc. (founded in 2008) and Impact Biomedicines, Inc. (founded in 2016).
He held the title of Chief Scientific Officer at Biosplice Therapeutics, Inc. and Chief Executive Officer at Impact Biomedicines, Inc. Dr. Hood is also the founder of Endeavor BioMedicines, Inc. Dr. Hood's current job(s) include being the Chief Executive Officer & Director at Actavalon, Inc. since 2018 and the Director at Nine Square Therapeutics, Inc. since 2022.
Dr. Hood's education history includes undergraduate and doctorate degrees from Texas A&M University.
John Hood active positions
| Companies | Position | Start |
|---|---|---|
Actavalon, Inc.
 Actavalon, Inc. Pharmaceuticals: MajorHealth Technology Actavalon, Inc. operates as a preclinical stage pharmaceutical company. It focuses on the development of a single, broad spectrum, drug with the potential to target and eradicate human cancer cells of all types such as breast, lung, pancreatic and colon cancer among others. The company was founded by Ned Israelsen and Wesley G. Hatfield and is headquartered in San Diego, CA. | Chief Executive Officer | - |
Endeavor BioMedicines, Inc
 Endeavor BioMedicines, Inc Miscellaneous Commercial ServicesCommercial Services Endeavor BioMedicines, Inc is a clinical stage company located in Solana Beach, CA, that develops novel therapies for fibrosis and oncology. The company's lead program, env-101, is a hedgehog signalling inhibitor currently in phase 2 studies treating IPF, a progressive interstitial lung disease that causes inflammation and scarring in the lung. The company's second program is a HER3-targeted ADC that will begin clinical development in 2024 for the treatment of multiple solid tumors. The company's mission is to develop transformative medicines by targeting the underlying genetic and cellular causes of disease with best in class agents. Endeavor is partnered with XCures and is currently looking at the LOF mutation. Regardless of eligibility for the Endeavor trial, XCures will still send a list of other treatment options that could work for the cancer mutation. The company was founded by Miguel A. de los Ríos and John Hood, with John Hood serving as the CEO since incorporation. | Chief Executive Officer | - |
Nine Square Therapeutics, Inc.
 Nine Square Therapeutics, Inc. BiotechnologyHealth Technology Nine Square Therapeutics, Inc. provides biotechnology services. The company was founded in 2020 and is headquartered in New York, NY. | Director/Board Member | 13/09/2022 |
Former positions of John Hood
| Companies | Position | End |
|---|---|---|
Impact Biomedicines, Inc.
 Impact Biomedicines, Inc. Medical SpecialtiesHealth Technology Impact Biomedicines, Inc. engages in the development of cancer treatments. It engages in the development of fedratinib, a potent and selective oral molecule JAK2 kinase inhibitor for the treatment of myelofibrosis and polycythemia vera. The company was founded by John Hood, Catriona Jamieson and Raghu Saripalli in 2016 and is headquartered in San Diego, CA. | Chief Executive Officer | 01/01/2018 |
Biosplice Therapeutics, Inc.
 Biosplice Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Biosplice Therapeutics, Inc. provides medical research and development for tissue-level regeneration. It develops therapeutics to address a range of degenerative diseases, regenerative medicine and oncology. The company was founded by Osman Kibar and John Hood in 2008 and is headquartered in San Diego, CA. | Founder | - |
Training of John Hood
| Texas A&M University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 5 |
|---|---|
Biosplice Therapeutics, Inc.
Biosplice Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Biosplice Therapeutics, Inc. provides medical research and development for tissue-level regeneration. It develops therapeutics to address a range of degenerative diseases, regenerative medicine and oncology. The company was founded by Osman Kibar and John Hood in 2008 and is headquartered in San Diego, CA. | Commercial Services |
Actavalon, Inc.
Actavalon, Inc. Pharmaceuticals: MajorHealth Technology Actavalon, Inc. operates as a preclinical stage pharmaceutical company. It focuses on the development of a single, broad spectrum, drug with the potential to target and eradicate human cancer cells of all types such as breast, lung, pancreatic and colon cancer among others. The company was founded by Ned Israelsen and Wesley G. Hatfield and is headquartered in San Diego, CA. | Health Technology |
Impact Biomedicines, Inc.
Impact Biomedicines, Inc. Medical SpecialtiesHealth Technology Impact Biomedicines, Inc. engages in the development of cancer treatments. It engages in the development of fedratinib, a potent and selective oral molecule JAK2 kinase inhibitor for the treatment of myelofibrosis and polycythemia vera. The company was founded by John Hood, Catriona Jamieson and Raghu Saripalli in 2016 and is headquartered in San Diego, CA. | Health Technology |
Nine Square Therapeutics, Inc.
Nine Square Therapeutics, Inc. BiotechnologyHealth Technology Nine Square Therapeutics, Inc. provides biotechnology services. The company was founded in 2020 and is headquartered in New York, NY. | Health Technology |
Endeavor BioMedicines, Inc
Endeavor BioMedicines, Inc Miscellaneous Commercial ServicesCommercial Services Endeavor BioMedicines, Inc is a clinical stage company located in Solana Beach, CA, that develops novel therapies for fibrosis and oncology. The company's lead program, env-101, is a hedgehog signalling inhibitor currently in phase 2 studies treating IPF, a progressive interstitial lung disease that causes inflammation and scarring in the lung. The company's second program is a HER3-targeted ADC that will begin clinical development in 2024 for the treatment of multiple solid tumors. The company's mission is to develop transformative medicines by targeting the underlying genetic and cellular causes of disease with best in class agents. Endeavor is partnered with XCures and is currently looking at the LOF mutation. Regardless of eligibility for the Endeavor trial, XCures will still send a list of other treatment options that could work for the cancer mutation. The company was founded by Miguel A. de los Ríos and John Hood, with John Hood serving as the CEO since incorporation. | Commercial Services |
- Stock Market
- Insiders
- John Hood